• news.cision.com/
  • ChemoTech/
  • Scandinavian ChemoTech’s Animal Care division signs exclusive distribution agreement for the Australian and New Zealand market

Scandinavian ChemoTech’s Animal Care division signs exclusive distribution agreement for the Australian and New Zealand market

Report this content

Vetiqure AB has today entered a strategic collaboration with Gamma Gurus Pty Ltd by signing an exclusive distribution agreement for the Australian and New Zealand veterinary market.

After over a 12-month extensive search and evaluation of over 20 potential distributors, we are very happy to announce that our top choice, Gamma Gurus, has now become a part of the Vetiqure family. This distribution agreement will generate one order of at least one vetIQure™ system, which will be activated after local ethics committee approval, before the end of January 2023.


Parallel to this agreement, ChemoTech is also in ongoing discussions with Gamma Gurus to expand into the human market with IQwave™.


“I am excited that we now can introduce our TSE technology to the Australian and New Zealand veterinary market, through a very established and knowledgeable distributor. This is truly an important market for Animal Care. It’s of course also a huge possibility for Human Care as Australia and New Zealand have the highest rates of skin cancer. We see our technology being able to make a difference as a new therapy in the fight against this form of cancer, amongst others.” – says Mohan Frick, CEO of Scandinavian ChemoTech AB


About Gamma Gurus Pty Ltd
Gamma Gurus brings over 100 years of experience in diagnostic imaging, radiation therapy and radioactive material management together in one place. Their goal is to provide unsurpassed solutions and service to their customers with a professional and hassle-free attitude. Their extensive network ensures that they will be able to source the best products from around the world to meet the needs of the local healthcare community. Their decades of local knowledge guarantee that suppliers and customers alike have the support to navigate the complex regulatory, logistics and technical nuances of the local markets.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-10-2022 15:30 CET.

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00


Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.